The goal of targeted therapeutics is to create drugs that by the specificity of their design and delivery will be more effective in treating disease and less toxic. Nanotechnology offers the possibility of a device and a drug in one, with novel capabilities. It will be necessary to address the challenges that lie ahead: targeted delivery, safety, commercialization and regulatory issues. Nanotechnology promises to create a new class of imaging agents that offer distinct advantages and can be used for the early detection and diagnosis of disease. Diagnostic molecules have the potential to act as biomarkers in drug development and diagnostics, and can be used in the imaging of cancer in living subjects. This meeting will address the challenges in implementing nanotechnology for drug delivery systems and imaging agents, and promote dialogue between diagnostic and therapeutic development.

• Extensive Focus on Delivery Strategies
• Regulatory and Safety Coverage
• Applications in Molecular Imaging
• New Partnering Forum for Early Stage Companies
• Nanoparticles in the Clinic

Scientific Advisory Board
Dr. Carol A. Dahl, Bill & Melinda Gates Foundation
Dr. Mauro Ferrari, The Ohio State University
Dr. Scott E. McNeil, NCI-Frederick
Dr. Celeste Null, Intel Corporation
Dr. Daniel C. Sullivan, National Cancer Institute
Dr. Stephen McCormack, NeuroSystec Corp.